NCT05466331 (DISCERNNE) is a NA clinical trial of Mobile Tele-HCV Care in Hepatitis C, sponsored by Baystate Medical Center.

Who is sponsoring NCT05466331?

NCT05466331 is sponsored by Baystate Medical Center.

What drugs are being tested in NCT05466331?

Interventions in NCT05466331: Mobile Tele-HCV Care, Enhanced Usual Care.

What condition does NCT05466331 study?

NCT05466331 studies Hepatitis C, Opioid Use Disorder, IV Drug Usage.

Is NCT05466331 still recruiting?

NCT05466331 is currently status unknown. Last updated 1 December 2023.

Last reviewed 2023-12-01 · How we verify

NCT05466331: DISCERNNE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rural New England Health Study (Phase 2)

Status unknown NA Last updated 1 December 2023

What this trial tests

NA trial testing Mobile Tele-HCV Care in Hepatitis C in 220 participants. Status unknown.

Timeline

18 May 2022

Primary endpoint
31 July 2024

31 July 2024

Quick facts

Lead sponsor	Baystate Medical Center
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	220
Start date	18 May 2022
Primary completion	31 July 2024
Estimated completion	31 July 2024
Sites	3 locations across United States

Drugs / interventions tested

Mobile Tele-HCV Care
Enhanced Usual Care

Conditions studied

Hepatitis C — all drugs for Hepatitis C →
Opioid Use Disorder — all drugs for Opioid Use Disorder →
IV Drug Usage — all drugs for IV Drug Usage →

Sponsor

Baystate Medical Center

Who can join

18 and older, any sex, with Hepatitis C or Opioid Use Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will integrate mobile hepatitis C virus (HCV) testing and treatment with expanded syringe access in order to improve uptake of HCV testing and treatment, and reduce syringe sharing behavior in rural northern New England. The intervention aims to reach rural opioid injectors with HCV and to fill service gaps identified around access to syringe services and HCV testing and treatment, while limiting the burden on local partners. If effective, this mobile model of HCV telehealth integrated with syringe services will provide a promising approach for local public health authorities seeking to curb opioid injection, syringe sharing and HCV rates in rural America, and reduce the risk environment for HIV outbreaks in those communities.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Mobile Telemedicine for Treating Chronic Hepatitis C Among Rural People Who Inject Drugs: A Randomized Clinical Trial.
Friedmann PD, Wilson D, de Gijsel D, Nolte K, et al · · 2026 · cited 3× · PMID 41587029 · DOI 10.1001/jamanetworkopen.2025.55125
Convenience, rapport and skill: effective rural hepatitis C treatment, qualitative findings from a mobile harm reduction-informed tele-medicine intervention in Northern New England, 2022-2024.
Nolte K, Del Toro-Mejias L, Bianchet E, Tarplin S, et al · · 2026 · PMID 41742143 · DOI 10.1186/s12954-026-01421-1

Verify or expand the search:

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
NCT05208697 — Tele-Harm Reduction · NA · active not recruiting

Other Baystate Medical Center trials

Trials by the same sponsor.

NCT07168642 — A Type I Hybrid Effectiveness-Implementation Trial of MIO · NA · recruiting
NCT07168629 — A Community Health Worker Intervention to Improve Lung Cancer Screening Uptake in Community Health Centers · NA · not yet recruiting
NCT07123480 — The Role of 4 Different Consent Approaches on a Pilot Study to Increase Cardiac Rehabilitation Attendance · NA · active not recruiting
NCT07019454 — Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysm · NA · recruiting
NCT06527820 — Aim 2 - Conversations Can Save Lives: TALKing About Buprenorphine & Methadone for Opioid Use Treatment Initiation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05466331 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Baystate Medical Center
Last refreshed: 1 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05466331.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing